Clinical bottom line
Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy is an emerging, putative treatment option for refractory membranoproliferative glomerulonephritis (MPGN) characterized by B cell–mediated pathology. Early clinical observations and mechanistic rationale suggest that targeting CD19-positive B cells may induce remission in cases unresponsive to conventional immunosuppression. However, current evidence is limited to case reports and extrapolation from hematologic and autoimmune diseases, warranting cautious interpretation. Prospective studies are needed to establish safety, efficacy, and patient selection criteria before routine clinical application.
What the evidence shows
MPGN is a heterogeneous glomerular disease often driven by immune complex deposition and dysregulated B cell activity. Conventional therapies include corticosteroids, immunosuppressants, and complement inhibitors, but refractory cases remain challenging. Anti-CD19 CAR-T therapy, originally developed for B cell malignancies, has demonstrated potent depletion of CD19+ B cells, offering a novel immunomodulatory approach.
Clinical data on anti-CD19 CAR-T therapy in MPGN are currently sparse. However, the therapy’s success in related B cell–mediated conditions provides a rationale for its exploration in refractory MPGN. For example, anti-CD19 CAR-T cells have achieved durable remissions in relapsed/refractory diffuse large B cell lymphoma (DLBCL) (Tirumala et al., 2026) and systemic lupus erythematosus (SLE) (Nutt et al., 2023; Saas et al., 2022; Ma et al., 2022), diseases sharing pathogenic B cell hyperactivity with MPGN. These reports highlight the potential for CAR-T therapy to reset aberrant immune responses.
Mechanistically, anti-CD19 CAR-T cells eliminate pathogenic B cell clones, potentially reducing immune complex formation and glomerular inflammation. Tirumala et al. (2026) describe fractionated dosing strategies that may improve safety and efficacy, which could be adapted for autoimmune renal diseases. Additionally, Tabbara et al. (2021) report successful anti-CD19 CAR-T therapy despite prior anti-CD19 antibody exposure, suggesting feasibility even in heavily pretreated patients.
While anti-CD22 CAR-T therapy has been investigated as a salvage option after anti-CD19 failure in B cell malignancies (Zhu et al., 2021), its role in MPGN remains unexplored. Overcoming resistance mechanisms to anti-CD19 CAR-T therapy, as reviewed in hematologic contexts (2021 review), may inform future nephrology applications.
Caveats and uncertainty
The evidence for anti-CD19 CAR-T therapy in MPGN is currently indirect and hypothesis-generating. No prospective clinical trials or large case series specifically address its use in MPGN. The safety profile in this population is unknown; CAR-T therapies carry risks including cytokine release syndrome and neurotoxicity, which may complicate management in patients with renal impairment.
MPGN’s heterogeneity and variable pathogenesis mean that not all patients may benefit from B cell–targeted therapy. Biomarkers to identify suitable candidates are lacking. Furthermore, the long-term effects of profound B cell depletion on infection risk and immune competence in MPGN patients require careful evaluation.
Cost, accessibility, and logistical challenges of CAR-T therapy also limit immediate clinical applicability. The need for specialized centers and multidisciplinary care may restrict use to refractory cases in research settings.
How this may change practice
If validated, anti-CD19 CAR-T therapy could represent a paradigm shift for refractory MPGN by providing a targeted immunotherapy option beyond conventional immunosuppression. It may offer durable remission for patients with B cell–driven disease unresponsive to existing treatments.
Clinicians should remain aware of ongoing research and emerging case reports, considering referral to clinical trials when available. Multidisciplinary collaboration between nephrologists, hematologists, and immunologists will be essential to optimize patient selection, monitoring, and management of adverse events.
In the near term, anti-CD19 CAR-T therapy remains investigational for MPGN. Its integration into practice will depend on accumulating robust clinical evidence demonstrating efficacy, safety, and cost-effectiveness in this specific renal indication.